Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company focusing on the discovery, acquisition, development and commercialization of proprietary therapeutics that target cancer stem cells (CSCs) and tumor bulk. In addition to developing StemScreen platform technology for the identification of novel CSC-directed compounds, Stemline is also developing SL-401, a biologic-drug conjugate which has completed Phase I/II clinical trial for relapsed/refractory acute myeloid leukemia. For more information, visit the company’s website at www.stemline.com.